AI assistant
X4 Pharmaceuticals, Inc — Director's Dealing 2017
Nov 15, 2017
34355_dirs_2017-11-15_27ec9451-640b-4535-a11f-a0594af7fe76.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15
Reporting Person: Mantus David (Chief Development Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $8.33 | 2026-02-03 | Common Stock (14649) | Direct | |
| Stock Option (right to buy) | $9.39 | 2026-07-19 | Common Stock (11719) | Direct | |
| Stock Option (right to buy) | $4.00 | 2027-06-18 | Common Stock (43949) | Direct |
Footnotes
F1: This option was granted on February 4, 2016 and vests over four years, with 25% of the original 14,649 shares underlying the option having vested on February 4, 2017 and 2.0833% of the original 14,649 shares vesting monthly thereafter, subject to continued service.
F2: This option was granted on July 20, 2016and vests over four years, with 25% of the original 11,719 shares underlying the option having vested on July 20, 2017 and2.0833% of the original 11,719 shares vesting monthly thereafter, subject to continued service.
F3: This option was granted on June 19, 2017and vests over four years, with 25% of the original 43,949 shares underlying the option vesting on June 19, 2018 and 2.0833% of the original 43,949 shares vesting monthly thereafter, subject to continued service.